司美格鲁肽治疗肥胖的研究进展

doi:10.3760/cma.j.issn.1007-1245.2022.07.003

摘要/Abstract

摘要： 全球范围内，肥胖已经成为一个严重的公共健康危机，且发病率不断增高。肥胖和一系列并发疾病给医疗保健系统带来了巨大负担，如何更有效减轻体质量已经成为当今社会的一个热点，仅靠单纯的生活干预很难控制，因此作为辅助手段的抗肥胖药物受到广泛的关注，但目前被批准用于减轻体资料的药物相对较少。司美格鲁肽是一种新型的胰高血糖素样肽-1受体激动剂（glucagon-like peptide-1 receptor agonist，GLP-1RA），相比传统的GLP-1RA，其具有半衰期长、稳定性高等优点。本文重点以司美格鲁肽治疗肥胖的研究进展进行讨论，为减轻肥胖提供一种新选择。

关键词: 司美格鲁肽, 肥胖, 胰高血糖素样肽-1受体激动剂

Abstract: Obesity has become a serious public health crisis in the whole world, and its incidence is increasing. Obesity and a series of concurrent diseases bring huge burden to the health care system. How to lose weight more effectively has become a hot spot in today's society, and it is difficult to control body weight only by life intervention. Therefore, anti-obesity drugs as an auxiliary means have received widespread attention, but relatively few drugs have been approved for weight loss. Semaglutide, a new glucagon-like peptide-1 receptor agonist (GLP-1RA), has the advantages of long half-life and high stability as compared with traditional GLP-1RA. This article focuses on the research progress of semaglutide in the treatment of obesity, which provides a new choice for reducing obesity.

Key words: Semaglutide, Obesity, Glucagon-like peptide-1 receptor agonist

邢国庆, 于苏国. 司美格鲁肽治疗肥胖的研究进展[J]. 国际医药卫生导报, 2022, 28(7): 898-901.

Xing Guoqing, Yu Suguo. Research progress of semaglutide in treatment of obesity[J]. International Medicine and Health Guidance News, 2022, 28(7): 898-901.

参考文献

[1] Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications [J]. Obes Facts, 2019, 12(2): 131-136. DOI: 10.1159/000497124.

[2] Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity [J]. Lancet, 2016, 387(10031): 1947-1956. DOI: 10.1016/S0140-6736(16)00271-3.

[3] Ralston J, Brinsden H, Buse K, et al. Time for a new obesity narrative [J]. Lancet, 2018, 392(10156):1384-1386. DOI: 10.1016/S0140-6736(18)32537-6.

[4] Ladenheim EE. Liraglutide and obesity: a review of the data so far [J]. Drug Des Devel Ther, 2015, 9: 1867-1875. DOI: 10.2147/DDDT.S58459.

[5] Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials [J]. Diabetes Obes Metab, 2018, 20(9): 2210-2219. DOI: 10.1111/dom.13353.

[6] Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update [J]. Int J Hypertens, 2013, 2013: 653789. DOI: 10.1155/2013/653789.

[7] Hussain A, Mahawar K, Xia Z, et al. Retraction notice to Obesity and Mortality of COVID-19. Meta-analysis [J]. Obes Res Clin Pract, 2021, 15(1): 100. DOI: 10.1016/j.orcp.2020.12.008.

[8] Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity [J]. N Engl J Med, 2019, 381(25): 2440-2450. DOI: 10.1056/NEJMsa1909301.

[9] Hope DCD, Tan TMM, Bloom SR. No guts, no loss: toward the ideal treatment for obesity in the twenty-first century [J]. Front Endocrinol (Lausanne), 2018, 9: 442. DOI: 10.3389/fendo.2018.00442.

[10] Saltiel AR. New therapeutic approaches for the treatment of obesity [J]. Sci Transl Med, 2016, 8(323): 323rv2. DOI: 10.1126/scitranslmed.aad1811.

[11] Sweeting AN, Hocking SL, Markovic TP. Pharmacotherapy for the treatment of obesity [J]. Mol Cell Endocrinol, 2015, 418 Pt 2: 173-183. DOI: 10.1016/j.mce.2015.09.005.

[12] Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity [J]. Endocr Pract, 2016, 22 Suppl 3: 1-203. DOI: 10.4158/EP161365.GL.

[13] Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline [J]. J Clin Endocrinol Metab, 2015, 100(2): 342-362. DOI: 10.1210/jc.　2014-3415.

[14] Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2985-3023. DOI: 10.1016/j.jacc.2013.11.004.

[15] Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity [J]. Diabetes Obes Metab, 2017, 19(9): 1242-1251. DOI: 10.1111/dom.12932.

[16] Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial [J]. Lancet Diabetes Endocrinol, 2017, 5(5):341-354. DOI: 10.1016/S2213-8587(17)30092-X.

[17] Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity [J]. Am J Health Syst Pharm, 2016, 73(19): 1493-1507. DOI: 10.2146/ajhp150990.

[18] GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years [J]. N Engl J Med, 2017, 377(1):13-27. DOI: 10.1056/NEJMoa1614362.

[19] Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial [J]. Diabetes Care, 2018, 41(2): 258-266. DOI: 10.2337/dc17-0417.

[20] Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10278): 971-984. DOI: 10.1016/S0140-6736(21)00213-0.

[21] Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes [J]. Diabetes Care, 2016, 39(2): 231-241. DOI: 10.2337/dc15-0165.

[22] O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial [J]. Lancet, 2018, 392(10148): 637-649. DOI: 10.1016/S0140-6736(18)31773-2.

[23] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity [J]. N Engl J Med, 2021, 384(11): 989. DOI: 10.1056/NEJMoa2032183.

[24] Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial [J]. JAMA, 2021, 325(14): 1403-1413. DOI: 10.1001/jama.2021.1831.

[25] Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss Maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial [J]. JAMA, 2021, 325(14): 1414-1425. DOI: 10.1001/jama.2021.　3224.